For someone receiving Casgevy (exagamglogene autotemcel), gene editing involves much more than an infusion. Blood stem cells ...

Japan’s largest drugmaker Takeda today announced that Orzeyful (oveporexton) is now available in Japan and China for the ...

French clinical-stage vaccine company Osivax said its Phase IIb field efficacy trial of OVX836, a nucleoprotein-based ...

Vir Biotechnology shares jumped nearly 10% in pre-market trading following a major licensing agreement with Gilead Sciences ...

The US regulator, the Food and Drug Administration (FDA), has launched an initiative to reshape rare disease drug development ...

US biotech company Verastem Oncology (Nasdaq: VSTM) has priced a $250 million offering alongside new results for its ...

French pharma major Sanofi (Euronext: SAN) must correct potentially misleading messages about a rival flu vaccine and ...

Life science investor Syncona announces that it has committed $10.1 million (£7.5 million) to a $310 million (£230 million) ...

Amsterdam-based precision oncology company iOnctura has appointed Paul Sekhri as chair of its board, with immediate effect, as it prepares for late-stage development of its lead drug, roginolisib. He ...

Switzerland's AL-S Pharma, a biotech developing antibodies against misfolded proteins in amyotrophic lateral sclerosis (ALS), ...